Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
65.94 USD +0.79% Intraday chart for Gilead Sciences, Inc. -1.51% -18.60%
Apr. 29 Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 MT
Apr. 26 TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • With an expected P/E ratio at 139.85 and 12.39 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • With an enterprise value anticipated at 3.57 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-18.60% 81.58B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Ratings Gilead Sciences, Inc.